IQVIA
Prescription drug sales at 340B prices softened for the second consecutive year compared with sales growth from 2019 to 2020, data in a new IQVIA white paper show.

340B Sales Growth Rate Softened for Second Straight Year, Data Show

Prescription drug sales at 340B prices grew 12.2% year-on-year from 2021 to 2022, drug industry consulting and research firm IQVIA says in a new white paper. That is down 3.7 percentage points compared with 340B sales growth from 2020 to 2021 and down 5.9 percentage points from 2019 to 2020.

IQVIA reported last year that 340B sales grew 15.9% year-on-year from 2020 to 2021. Before that it reported 340B sales growth of 18.1% from 2019 to 2020 and 17.1% from 2018 to 2019. Drug manufacturers began restricting sales at 340B prices in mid 2020, a trend that accelerated through 2022 and kept growing this year.

Prescription drug sales at 340B prices grew 12.2% year-on-year from 2021 to 2022, drug industry consulting and research firm IQVIA says in a new white paper. That is down 3.7 percentage points compared with 340B sales growth from 2020 to […]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

×

*Sign up for news summaries and alerts from 340B Report

Site Footer